• E-64 and the Evidence for Lysoptosis

  2026-10-13

  Existing evidence supports lysoptosis as a cathepsin-dependent lysosomal death program in selected genetic and epithelial models, but it does not establish that E-64 was used in the defining comparison or that pharmacological cysteine protease inhibition alone identifies this pathway. The main evidence gaps concern pathway specificity, cross-model reproducibility, and translation beyond the studied systems.

• Tunicamycin and ER Stress: Evidence in Context

  2026-10-13

  Tunicamycin is described by APExBIO as a N-glycosylation inhibitor and endoplasmic reticulum stress inducer. The supplied hepatitis C virus study used tunicamycin as a comparative ER-stress model while primarily investigating whether naringenin modulates IRE1α–XBP1 signaling and hepatic insulin resistance. The findings support a mechanistic association, but they do not establish clinical efficacy or validate tunicamycin as a treatment.

• Procainamide and Cisplatin in Pregnant Mice

  2026-10-12

  A 2006 mouse study examined whether procainamide hydrochloride could accompany cisplatin without worsening embryotoxicity. The findings suggest no additional embryotoxic signal in the tested model and modest improvements in selected fetal endpoints, but they do not establish clinical safety, efficacy, or applicability to human pregnancy.

• HNF4A-AS1 and Sorafenib Resistance in HCC

  2026-10-12

  The 2024 Theranostics study links reduced HNF4A-AS1 with sorafenib resistance and altered lipid metabolism in hepatocellular carcinoma models. Its multi-model findings support a mechanistic hypothesis involving m6A regulation, DECR1, polyunsaturated fatty acids, and ferroptosis, but they do not establish clinical utility or show that glucose uptake caused the reported phenotype. The 2-NBDG Glucose Uptake Assay Kit is a separate fluorescent glucose-uptake product whose documented scope should not be conflated with the study’s lipid-metabolism evidence.

• Cytochalasin B: Evidence, Context, and Limits

  2026-10-11

  Cytochalasin B is presented as an actin-directed cytoskeletal research tool, but the supplied heat-not-burn toxicology study does not evaluate Cytochalasin B or actin biology. Its findings support only a product-specific, endpoint-limited comparison and do not establish clinical safety or broader toxicological conclusions.

• SARS-CoV-2 NSP15 Screening: Thymopentin and Oleuropein

  2026-10-10

  A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 NSP15 endoribonuclease and identified thymopentin and oleuropein as the strongest predicted binders. Molecular dynamics supported persistence of the modeled complexes, but the findings remain computational and require biochemical, cellular, and in vivo validation before antiviral activity can be inferred.

• TUNEL Apoptosis Detection Kit: Evidence and Limits

  2026-10-09

  The TUNEL Apoptosis Detection Kit supports DNA fragmentation detection in apoptosis through a TdT–biotin–streptavidin-HRP signal system with DAB visualization. It is useful for tissue sections and cultured cells, but a TUNEL-positive signal does not independently establish apoptosis or disease mechanism.

• Rosiglitazone and Variant-Aware PPARγ Research

  2026-10-09

  Rosiglitazone is more than a reference PPARγ agonist: it can help distinguish ligand responsiveness from receptor instability in metabolic research. This article interprets the PPARG R212W study, explains its evidence limits, and develops a genotype-aware framework for studying adipocyte dysfunction.

• Clozapine N-oxide in Circuit Neuroscience

  2026-10-08

  Clozapine N-oxide (CNO) is widely associated with DREADD-based chemogenetics, but its interpretation requires pharmacological caution. This overview examines its research context, the reported exercise–depression circuit findings in a doctoral thesis, the contrast between chemogenetic and optogenetic evidence, and limitations affecting translation from male-mouse models to human neuroscience.

• Sulfisomidine in Pertussis: Findings and Limits

  2026-10-08

  The 1956 report on sulfisomidine in pertussis combined clinical observation with serial blood and urine measurements, offering an early pharmacokinetic and safety perspective in a small pediatric case series. Its findings support historical feasibility and describe drug exposure, but the combined treatment design and lack of a comparator limit conclusions about efficacy or present-day clinical use.

• β-Amanitin: Research Context and Evidence

  2026-10-07

  A source-grounded overview of beta-amanitin, RNA polymerase II research, amatoxin toxicology, and a 2026 dual-target mushroom toxin detection study, including reported performance, evidence comparisons, and applicability limits.

• Acetylation-Related Biomarkers in Osteoarthritis

  2026-10-07

  A 2026 PLOS One study integrated transcriptomic datasets, co-expression analysis, machine learning, immune-infiltration estimates, and experimental validation to identify JUN and MYC as candidate acetylation-related osteoarthritis biomarkers. The findings are promising for biomarker discovery, but the validation gap between training and independent datasets means the results require broader clinical and mechanistic confirmation.

• Polygodial: From TRPA1 Activation to Evidence

  2026-10-06

  Polygodial is a TRPA1 channel activator that helps frame questions about calcium signaling, epithelial inflammation, and sensory biology. This evidence-focused analysis explains how the TRPV1/TRPA1–Ca²⁺/NFAT findings in nasal epithelial cells inform interpretation without overstating what Polygodial itself has demonstrated.

• Trelagliptin, RUNX2, and Osteoblast Differentiation

  2026-10-06

  A 2021 Bioengineered study reports that the DPP-4 inhibitor trelagliptin promotes osteoblastic differentiation and mineralization in MC3T3-E1 cells, with increased RUNX2 expression and AMPK activation. The findings suggest a possible bone-forming mechanism, but the evidence remains limited to an in vitro murine cell model and does not establish clinical efficacy in osteoporosis.

• Isoproterenol Sulfate Dihydrate in Pacemaker Research

  2026-10-05

  Isoproterenol sulfate dihydrate is a non-selective beta-adrenergic agonist relevant to cAMP/PKA pathway studies and cardiovascular research. In human sinoatrial node assembloids, it is best framed as a conceptual pharmacological challenge for beta-receptor responsiveness, not as a reported probe of the PSAP–GPR37 maturation mechanism.

8563 records 1/571 page Next 12345 下5页 Last page